Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study

BACKGROUND: The aim was to evaluate long‐term effectiveness and safety of lanadelumab in patients ≥12 y old with hereditary angioedema (HAE) 1/2 (NCT02741596). METHODS: Rollover patients completing the HELP Study and continuing into HELP OLE received one lanadelumab 300 mg dose until first attack (d...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerji, Aleena, Bernstein, Jonathan A., Johnston, Douglas T., Lumry, William R., Magerl, Markus, Maurer, Marcus, Martinez‐Saguer, Inmaculada, Zanichelli, Andrea, Hao, James, Inhaber, Neil, Yu, Ming, Riedl, Marc A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292251/
https://www.ncbi.nlm.nih.gov/pubmed/34287942
http://dx.doi.org/10.1111/all.15011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292251/
https://www.ncbi.nlm.nih.gov/pubmed/34287942
http://dx.doi.org/10.1111/all.15011

Ejemplares similares